PCIDB

KNApSAcK Metabolite C00019674

Metabolite

KNApSAcK Entry

id C00019674
Name Uridine
CAS RN 58-96-8
Standard InChI InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6?,7+,8-/m1/s1
Standard InChI (Main Layer) InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)

Cluster

Phytochemical cluster
KCF-S cluster No. 2366

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL68846 CHEMBL100259 CHEMBL265701 CHEMBL608294 CHEMBL609651 CHEMBL1092065 CHEMBL2093066

KEGG

By LinkDB C00299

CTD

By CAS RN D014529

Human Protein / Gene in interaction

5 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL1092065 CHEMBL1693776 (1)
0 / 3
P27708 CAD protein Enzyme CHEMBL100259 CHEMBL653965 (1)
0 / 0
O75496 Geminin Unclassified protein CHEMBL100259 CHEMBL2114780 (1)
0 / 0
Q9HA47 Uridine-cytidine kinase 1 Enzyme CHEMBL100259 CHEMBL910979 (2) CHEMBL910978 (1)
0 / 0
Q9UNA4 DNA polymerase iota Enzyme CHEMBL100259 CHEMBL1794483 (1)
0 / 0

CTD interaction (26)

compound gene gene name gene description interaction interaction type form reference
pmid
D014529 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Uridine results in increased expression of FASLG protein increases expression
protein 16419169
D014529 2993 GYPA
CD235a
GPA
GPErik
GPSAT
HGpMiV
HGpMiXI
HGpSta(C)
MN
MNS
PAS-2
glycophorin A (MNS blood group) Uridine inhibits the reaction [A 771726 results in increased expression of GYPA protein] decreases reaction
/ increases expression
protein 12181422
D014529 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein] decreases expression
/ decreases reaction
protein 9808420
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9124315
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Cytarabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] decreases reaction
/ increases transport
protein 10772724
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Cytidine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9124315
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 gemcitabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] decreases reaction
/ increases transport
protein 10772724
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Lamivudine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] decreases reaction
/ increases transport
protein 10772724
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 SLC28A1 protein results in increased transport of Uridine increases transport
protein 10772724
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 SLC28A1 protein results in increased uptake of Uridine increases uptake
protein 9124315
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Sodium affects the reaction [SLC28A1 protein results in increased uptake of Uridine] affects reaction
/ increases uptake
protein 9124315
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Thymidine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9124315
D014529 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 Zidovudine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9124315
D014529 9153 SLC28A2
CNT2
HCNT2
HsT17153
SPNT1
solute carrier family 28 (concentrative nucleoside transporter), member 2 SLC28A2 protein results in increased transport of Uridine increases transport
protein 10087507
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine] affects cotreatment
/ decreases reaction
/ increases uptake
protein 10366666
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9353301
9396714
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 Dilazep inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9353301
9396714
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9353301
9396714
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] affects cotreatment
/ decreases reaction
/ increases reaction
/ increases uptake
protein 10366666
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 Lidoflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] decreases reaction
/ increases uptake
protein 9396714
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 [SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine affects cotreatment
/ increases uptake
protein 10366666
D014529 2030 SLC29A1
ENT1
solute carrier family 29 (equilibrative nucleoside transporter), member 1 SLC29A1 protein results in increased uptake of Uridine increases uptake
protein 9353301
9396714
10366666
18381442
D014529 3177 SLC29A2
DER12
ENT2
HNP36
solute carrier family 29 (equilibrative nucleoside transporter), member 2 4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine] affects cotreatment
/ decreases reaction
/ increases uptake
protein 10366666
D014529 3177 SLC29A2
DER12
ENT2
HNP36
solute carrier family 29 (equilibrative nucleoside transporter), member 2 Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] affects cotreatment
/ decreases reaction
/ increases reaction
/ increases uptake
protein 10366666
D014529 3177 SLC29A2
DER12
ENT2
HNP36
solute carrier family 29 (equilibrative nucleoside transporter), member 2 [SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine affects cotreatment
/ increases uptake
protein 10366666
D014529 3177 SLC29A2
DER12
ENT2
HNP36
solute carrier family 29 (equilibrative nucleoside transporter), member 2 SLC29A2 protein results in increased uptake of Uridine increases uptake
protein 9396714
10366666

Related Disease

Diseases related to proteins in ChEMBL interactions

KEGG DISEASE (3)

KEGG disease name UniProt
H00017 Esophageal cancer P35354 (related)
H00025 Penile cancer P35354 (related)
H00046 Cholangiocarcinoma P35354 (related)

Diseases related to CTD interactions

15 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000015 D014529 Abnormalities, Multiple therapeutic
19190124
D000749 D014529 Anemia, Megaloblastic therapeutic
1036874
D001919 D014529 Bradycardia marker/mechanism
18313046
D002375 D014529 Catalepsy marker/mechanism
20504471
D004342 D014529 Drug Hypersensitivity therapeutic
2472021
D056486 D014529 Drug-Induced Liver Injury therapeutic
17187420
D064420 D014529 Drug-Related Side Effects and Adverse Reactions therapeutic
2257295
D005234 D014529 Fatty Liver therapeutic
17187420
D007022 D014529 Hypotension marker/mechanism
18313046
D028361 D014529 Mitochondrial Diseases therapeutic
8232219
17187420
C538525 D014529 Mitochondrial encephalopathy therapeutic
20032772
D017240 D014529 Mitochondrial Myopathies therapeutic
18163507
D010523 D014529 Peripheral Nervous System Diseases therapeutic
20032772
D011565 D014529 Psoriasis marker/mechanism
1036874
D019956 D014529 Stereotypic Movement Disorder marker/mechanism
20504471